Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges

被引：18

作者：

Koutras, A. K. ^{[1
]}

Starakis, I. ^{[1
]}

Kyriakopoulou, U. ^{[1
]}

Katsaounis, P. ^{[1
]}

Nikolakopoulos, A. ^{[1
]}

Kalofonos, H. P. ^{[1
]}

机构：

[1] Univ Hosp Patras, Div Oncol, Dept Med, Rion, Greece

来源：

CURRENT MEDICINAL CHEMISTRY | 2011年 / 18卷 / 11期

关键词：

Bevacizumab; cetuximab; colorectal cancer; panitumumab; targeted therapy; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; CETUXIMAB PLUS IRINOTECAN; MONOCLONAL-ANTIBODY; KRAS MUTATIONS; 1ST-LINE TREATMENT; TUMOR-GROWTH; PANITUMUMAB MONOTHERAPY; IONIZING-RADIATION; INDUCED ACTIVATION;

D O I：

10.2174/092986711795471338

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab/panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.

引用

页码：1599 / 1612

页数：14

共 144 条

[91]

Peeters M, 2009, EUROPEAN J CANC S

[92]

Peng D, 1996, CANCER RES, V56, P3666

[93]

Perrotte P, 1999, CLIN CANCER RES, V5, P257

[94]

Prewett MC, 2002, CLIN CANCER RES, V8, P994

[95] Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy [J].

Pueya, Gemma ;

Mesia, Ricard ;

Figueras, Agnes ;

Lozano, Alicia ;

Baro, Marta ;

Vazquez, Silvia ;

Capella, Gabriel ;

Balart, Josep .

ONCOLOGIST, 2010, 15 (09) :976-986

[96]

Purdie D. M., 2008, J CLIN ONCOLOGY

[97] Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival [J].

Reinmuth, N ;

Liu, WB ;

Jung, YD ;

Ahmad, SA ;

Shaheen, RM ;

Fan, F ;

Bucana, CD ;

McMahon, G ;

Gallick, GE ;

Ellis, LM .

FASEB JOURNAL, 2001, 15 (07) :1239-1241

[98] Cetuximab - In the treatment of metastatic colorectal cancer [J].

Reynolds, NA ;

Wagstaff, AJ .

DRUGS, 2004, 64 (01) :109-118

[99] Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis [J].

Ridgway, John ;

Zhang, Gu ;

Wu, Yan ;

Stawicki, Scott ;

Liang, Wei-Ching ;

Chanthery, Yvan ;

Kowalski, Joe ;

Watts, Ryan J. ;

Callahan, Christopher ;

Kasman, Ian ;

Singh, Mallika ;

Chien, May ;

Tan, Christine ;

Hongo, Jo-Anne S. ;

de Sauvage, Fred ;

Plowman, Greg ;

Yan, Minhong .

NATURE, 2006, 444 (7122) :1083-1087

[100] Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer [J].

Robert, F ;

Ezekiel, MP ;

Spencer, SA ;

Meredith, RF ;

Bonner, JA ;

Khazaeli, MB ;

Saleh, MN ;

Carey, D ;

LoBuglio, AF ;

Wheeler, RH ;

Cooper, MR ;

Waksal, HW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3234-3243

← 5 6 7 8 9 10 11 12 13 14 →